Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022350 | 0.91 | PTGS2 (0.49) | PTGS2PTGS1PDE5AHSD17B1PGR | |
| SCHEMBL1021324 | 0.90 | PTGS2 (0.48) | PTGS2PTGS1PDE5AHSD17B1PGR | |
| SCHEMBL1025830 | 0.88 | PTGS2 (0.54) | PTGS2PTGS1PDE5AHSD17B1PGR | |
| SCHEMBL1019980 | 0.83 | PTGS1 (0.48) | PTGS2PTGS1GCGR | |
| SCHEMBL1021420 | 0.81 | PTGS2 (0.50) | PTGS2PTGS1PDE5AHSD17B1PGR | |
| SCHEMBL1022426 | 0.79 | HSD17B1 (0.47) | PTGS2PTGS1HSD17B1RARARARB | |
| SCHEMBL1022437 | 0.78 | PTGS2 (0.34) | PTGS2PTGS1GCGR | |
| SCHEMBL1022436 | 0.78 | PTGS2 (0.34) | PTGS2PTGS1GCGR | |
| SCHEMBL1023688 | 0.78 | PTGS2 (0.51) | PTGS2PTGS1PGRRARARARB | |
| SCHEMBL1021898 | 0.77 | MGLL (0.41) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | claimed |
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | disclosed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | disclosed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | disclosed |
| EP-1841729-A1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | Amorepacific Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006059867-A1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORPORATION (KR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | TNF, PDE4A, PDE3B | PTGS2 27/4885PTGS1 15/4885PDE5A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.